Rare Access Action Project (RAAP)

Washington – September 23, 2026 -- Bristol Myers Squibb (BMS) has joined the Rare Access Action Project (RAAP), adding a major biopharmaceutical player to a coalition working to resolve coverage and access barriers for rare disease patients.

RAAP expands coalition with BMS to tackle patient access barriers

RAAP, a coalition of patient advocates and life sciences companies, confirmed BMS's membership as part of its ongoing effort to develop policy solutions for structural access and coverage gaps affecting rare disease patients. Michael Eging, Executive Director of RAAP, said BMS brings a long history of scientific innovation and a strong commitment to patients facing serious and complex diseases.